Literature DB >> 20937349

Development of an in vitro alternative assay method for vaginal irritation.

Seyoum Ayehunie1, Chris Cannon, Karen Larosa, Jeffrey Pudney, Deborah J Anderson, Mitchell Klausner.   

Abstract

The vaginal mucosa is commonly exposed to chemicals and therapeutic agents that may result in irritation and/or inflammation. In addition to acute effects, vaginal irritation and inflammation can make women more susceptible to infections such as HIV-1 and herpes simplex virus 2 (HSV-2). Hence, the vaginal irritation potential of feminine care formulations and vaginally administered therapeutic agents is a significant public health concern. Traditionally, testing of such materials has been performed using the rabbit vaginal irritation (RVI) assay. In the current study, we investigated whether the organotypic, highly differentiated EpiVaginal™ tissue could be used as a non-animal alternative to the RVI test. The EpiVaginal tissue was exposed to a single application of ingredients commonly found in feminine hygiene products and the effects on tissue viability (MTT assay), barrier disruption (measured by transepithelial electrical resistance, TEER and sodium fluorescein (NaFl) leakage), and inflammatory cytokine release (interleukin (IL)-1α, IL-1β, IL-6, and IL-8) patterns were examined. When compared to untreated controls, two irritating ingredients, nonoxynol 9 and benzalkonium chloride, reduced tissue viability to <40% and TEER to <60% while increasing NaFl leakage by 11-24% and IL-1α and IL-1β release by >100%. Four other non-irritating materials had minimal effects on these parameters. Assay reproducibility was confirmed by testing the chemicals using three different tissue production lots and by using tissues reconstructed from cells obtained from three different donors. Coefficients of variation between tissue lots reconstructed with cells obtained from the same donor or lots reconstructed with cells obtained from different donors were less than 10% and 12%, respectively. In conclusion, decreases in tissue viability and barrier function and increases in IL-1α and IL-1β release appear to be useful endpoints for preclinical screening of topically applied chemicals and formulations for their vaginal irritation potential.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937349      PMCID: PMC3003762          DOI: 10.1016/j.tox.2010.10.001

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  34 in total

1.  Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid.

Authors:  Nitya Venkataraman; Amy L Cole; Pavel Svoboda; Jan Pohl; Alexander M Cole
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 2.  Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa.

Authors:  Christopher A Squier; Mary J Mantz; Patrick M Schlievert; Catherine C Davis
Journal:  J Pharm Sci       Date:  2008-01       Impact factor: 3.534

3.  Comparative safety evaluation of the candidate vaginal microbicide C31G.

Authors:  Bradley J Catalone; Tina M Kish-Catalone; Elizabeth B Neely; Lynn R Budgeon; Mary L Ferguson; Catherine Stiller; Shendra R Miller; Daniel Malamud; Fred C Krebs; Mary K Howett; Brian Wigdahl
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Evaluation of tissue culture insert membrane compatibility in the fluorescein leakage assay.

Authors:  R K Ward; S Mungall; J Carter; R H Clothier
Journal:  Toxicol In Vitro       Date:  1997-12       Impact factor: 3.500

5.  Ultrastructural analysis of interleukin-1 beta-induced leukocyte recruitment to the rat retina.

Authors:  S D Bamforth; S L Lightman; J Greenwood
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-01       Impact factor: 4.799

Review 6.  Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety.

Authors:  James E Cummins; Gustavo F Doncel
Journal:  Sex Transm Dis       Date:  2009-03       Impact factor: 2.830

7.  Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women.

Authors:  L Bélec; R Gherardi; C Payan; T Prazuck; J E Malkin; C Tévi-Bénissan; J Pillot
Journal:  Cytokine       Date:  1995-08       Impact factor: 3.861

8.  Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives.

Authors:  R N Fichorova; M Bajpai; N Chandra; J G Hsiu; M Spangler; V Ratnam; G F Doncel
Journal:  Biol Reprod       Date:  2004-05-05       Impact factor: 4.285

9.  Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques.

Authors:  Che-Chung Tsai; Peter Emau; Yonghou Jiang; Baoping Tian; William R Morton; Kirk R Gustafson; Michael R Boyd
Journal:  AIDS Res Hum Retroviruses       Date:  2003-07       Impact factor: 2.205

10.  Safety study of an antimicrobial peptide lactocin 160, produced by the vaginal Lactobacillus rhamnosus.

Authors:  Sara E Dover; Alla A Aroutcheva; S Faro; Michael L Chikindas
Journal:  Infect Dis Obstet Gynecol       Date:  2007
View more
  14 in total

Review 1.  On the genealogy of tissue engineering and regenerative medicine.

Authors:  Himanshu Kaul; Yiannis Ventikos
Journal:  Tissue Eng Part B Rev       Date:  2014-12-23       Impact factor: 6.389

2.  Preclinical evaluation of UC781 microbicide vaginal drug delivery.

Authors:  Meredith R Clark; Timothy J McCormick; Gustavo F Doncel; David R Friend
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

3.  Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro.

Authors:  Kevin M Tyo; Hung R Vuong; Danial A Malik; Lee B Sims; Houda Alatassi; Jinghua Duan; Walter H Watson; Jill M Steinbach-Rankins
Journal:  Int J Pharm       Date:  2017-08-07       Impact factor: 5.875

4.  Characterization of a Hormone-Responsive Organotypic Human Vaginal Tissue Model: Morphologic and Immunologic Effects.

Authors:  Seyoum Ayehunie; Ayesha Islam; Chris Cannon; Timothy Landry; Jeffrey Pudney; Mitchell Klausner; Deborah J Anderson
Journal:  Reprod Sci       Date:  2015-02-11       Impact factor: 3.060

5.  Impact of Hydroxychloroquine-Loaded Polyurethane Intravaginal Rings on Lactobacilli.

Authors:  Yannick Leandre Traore; Yufei Chen; Anne-Marie Bernier; Emmanuel A Ho
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

6.  Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment.

Authors:  Sujata Sundara Rajan; Yevgeniy Turovskiy; Yashveer Singh; Michael L Chikindas; Patrick J Sinko
Journal:  J Control Release       Date:  2014-09-16       Impact factor: 9.776

7.  Engineering and characterization of simplified vaginal and seminal fluid simulants.

Authors:  Rachna Rastogi; Jonathan Su; Alamelu Mahalingam; Justin Clark; Samuel Sung; Thomas Hope; Patrick F Kiser
Journal:  Contraception       Date:  2015-11-14       Impact factor: 3.375

8.  Establishment and characterization of a differentiated epithelial cell culture model derived from the porcine cervix uteri.

Authors:  Katrin Miessen; Ralf Einspanier; Jennifer Schoen
Journal:  BMC Vet Res       Date:  2012-03-19       Impact factor: 2.741

9.  Nanoparticle transport from mouse vagina to adjacent lymph nodes.

Authors:  Byron Ballou; Susan K Andreko; Elvira Osuna-Highley; Michael McRaven; Tina Catalone; Marcel P Bruchez; Thomas J Hope; Mohamed E Labib
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

10.  Anti-Retroviral Lectins Have Modest Effects on Adherence of Trichomonas vaginalis to Epithelial Cells In Vitro and on Recovery of Tritrichomonas foetus in a Mouse Vaginal Model.

Authors:  Aparajita Chatterjee; Daniel M Ratner; Christopher M Ryan; Patricia J Johnson; Barry R O'Keefe; W Evan Secor; Deborah J Anderson; Phillips W Robbins; John Samuelson
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.